---
title: "Descartes-08 in Generalized myasthenia gravis: MG-001 phase 2b"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: MG-001 phase 2b. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 81 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence/mg-001-phase-2b"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: MG-001 phase 2b

<a id="heading-3.1.2"></a>

## 3.1.2 MG-001 Phase 2b

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Objective: efficacy and safety of Descartes-08 versus placebo in generalized MG

> “Here, we report the efficacy and safety of Descartes-08 for the treatment of gMG in a phase 2b, randomized, double-blind, placebo-controlled trial (MG-001 part 3).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.1-2"></a>

#### Registered objective of the phase 2b study

> “This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis”
> “In Part 3, the primary objective is to compare the effect of Descartes-08 versus placebo, as measured by the change in MGC score from baseline to Week 12.”

Source: [ClinicalTrials.gov NCT04146051](https://clinicaltrials.gov/study/NCT04146051)

<a id="topic-3.1.2.1-3"></a>

#### Objective as stated in the September 2025 congress poster

> “Assess the efficacy of Descartes-08 versus placebo in adults with gMG using the MG Composite (MGC) score at Month 3.”

Source: [Vu et al. (2025)](https://www.cartesiantherapeutics.com/wp-content/uploads/NMSG-Poster_09.26.25.pdf)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Settings and countries

> “MG-001 part 3 was a phase 2b, randomized, double-blind, placebo-controlled trial of Descartes-08 in patients with MGFA class II–IV gMG, conducted in academic medical centers and community neurology clinics in North America and Türkiye (ClinicalTrials.gov identifier: NCT04146051).”
> “The trial was approved by regulatory authorities in each country (USA, Canada and Türkiye), the central and local institutional review boards in the USA (Western Institutional Review Board-Copernicus Group, WCG IRB, Puyallup, WA), and the ethics committee at each site in other countries (the research ethics boards at the University of Toronto and the University of Alberta, as well as the ethics committee at Istanbul University).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.2-2"></a>

#### Screening period, November 2022 to January 2024

> “A total of 50 participants were screened for eligibility in this study (MG-001 part 3) between November 10, 2022, and January 15, 2024 (Fig. 1).”
> “Part 3 was added to the MG-001 study protocol in amendment v3.0 (August 1, 2022).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Randomized, double-blind, placebo-controlled design with 12-month follow-up

> “In this phase 2b, double-blind, placebo-controlled trial, eligible patients with gMG who tested negative for autoantibodies to MuSK were randomized 1:1 to receive six once-weekly intravenous infusions of Descartes-08 or placebo.”
> “The study included a 12-month follow-up period to assess the efficacy of treatment using the MG Composite (MGC), MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) scores.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.3-2"></a>

#### Leukapheresis before randomization and placebo manufacture

> “All eligible participants underwent leukapheresis and had a Descartes-08 lot and an acellular placebo lot manufactured under Good Manufacturing Practice conditions.”
> “Following the successful manufacturing of the autologous product, participants enrolled in part 3 were randomized 1:1 to receive either Descartes-08 or placebo.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.3-3"></a>

#### Randomization and allocation concealment

> “Randomization was performed centrally using a computer-generated permuted-block scheme without stratification (Mathematica v13.0, Wolfram Research).”
> “Block sizes were varied and concealed from site personnel to maintain unpredictability in allocation.”
> “The random allocation sequence was generated by the study statistician and implemented centrally at the autologous lot manufacturing stage by sponsor staff who were otherwise uninvolved in the study conduct.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.3-4"></a>

#### Blinding through the month 3 primary endpoint assessment

> “Participants, study team members and all sponsor staff involved in the treatment or clinical evaluation of the patients, as well as in the review or analysis of data, were blinded to the treatment assignment until after the primary endpoint assessment.”
> “Blinding of study personnel, clinic staff and participants during infusion was maintained using opaque coverings for the infusion bag and tubing, which were identical between Descartes-08 and placebo.”
> “Blinded follow-up occurred at 2 weeks (month 2) and 6 weeks (month 3) after the last infusion.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.3-5"></a>

#### Open-label crossover after month 3 and 12-month follow-up

> “Both the study teams and participants were blinded to the treatment assignment through the month 3 visit.”
> “After the primary endpoint assessment at month 3, participants randomized to placebo had the option to cross over to Descartes-08, which was administered under an open-label protocol.”
> “All participants were followed up for 12 months.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.3-6"></a>

#### Rescue therapy

> “Participants who demonstrated a ≥3-point worsening of the MG-ADL score from baseline or showed signs of an impending myasthenic crisis could receive rescue therapy, which, for those randomized to placebo, included Descartes-08.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.3-7"></a>

#### Independent study monitoring committee

> “Oversight of the study was provided by an independent study monitoring committee comprising a neurologist, a hematologist specializing in cell therapy and a statistician.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.3-8"></a>

#### Protocol amendments: enrollment cap, primary endpoint, and primary efficacy population

> “Major amendments include v3.2 (October 17, 2023), which increased the enrollment cap to 50; v3.3 (January 8, 2024), which specified a 5-point reduction in the MGC score at month 3 as the primary endpoint; and v4.2 (June 19, 2024), which defined the primary efficacy population and outlined the use of the estimand framework for intercurrent events.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion criteria: age, MGFA class, background immunosuppression, and corticosteroid dose

> “All participants were required to meet the following inclusion criteria: ≥18 years of age; a diagnosis of gMG, defined as MGFA clinical class III or IV (part 1; dose escalation) or class II–IV (parts 2–4) at the time of screening; use of concomitant immunosuppressive drugs deemed necessary by the investigator; daily dose of corticosteroids of ≤40 mg per day of prednisone equivalent, with a stable dose for a minimum of 4 weeks before the baseline visit”
> “participants must have an MG-ADL total score of ≥6.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.4-2"></a>

#### Inclusion criteria: seropositive and seronegative cohorts

> “for the seropositive cohort only: MG-specific antibody titer must be above the reference laboratory’s upper limit of normal and documented within 10 years of screening (patients who were MuSK or LRP4 autoantibody-positive were allowed to be enrolled in parts 1 and 2 only and were not eligible for this trial)”
> “for the seronegative cohort only: unequivocal response to cholinesterase inhibitors and abnormal repetitive nerve stimulation or increased jitter (participants must not have another neuromuscular disease that may cause increased jitter and must have a negative congenital myasthenic syndrome panel)”
> “Participants who tested positive for MuSK autoantibodies were excluded from the study.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.4-3"></a>

#### Exclusion criteria: recent IVIg, plasma exchange, B-cell therapy, and biologics

> “intravenous infusion of immunoglobulin or plasma exchange within 4 weeks before the baseline (day 1) visit; treatment with rituximab or ocrelizumab within 12 months before the baseline (first infusion) visit; treatment with calcineurin inhibitors (for example, tacrolimus, cyclosporine, cyclophosphamide), FcRn antagonists and/or other biologics within 3 weeks before the planned leukapheresis and within 8 weeks before the baseline (first infusion) visit; initiation of eculizumab treatment within 8 weeks before the baseline (first infusion) visit (patients who had been receiving eculizumab for more than 8 weeks and met other criteria for enrollment were eligible for treatment on the trial)”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.4-4"></a>

#### Exclusion criteria: immunodeficiency, infection, malignancy, and live vaccines

> “history of primary immunodeficiency or organ or allogeneic bone marrow transplant”
> “active tuberculosis or a positive QuantiFERON test at screening”
> “a history of malignancy that required treatment in the past 3 years, except for successfully treated squamous cell and/or basal cell carcinoma of the skin and/or breast or colon cancer that was surgically removed and did not require adjuvant chemotherapy or radiotherapy”
> “receipt of a live vaccination within 4 weeks before baseline (day 1) or intent to receive live vaccination during the study”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Six once-weekly infusions of Descartes-08 or placebo with 12-month follow-up

> “Patients eligible for inclusion were randomized 1:1 to receive either six once-weekly intravenous infusions of Descartes-08 or placebo with a 12-month follow-up period post infusion (Figure 1).”

Source: [Vu et al. (2025)](https://www.cartesiantherapeutics.com/wp-content/uploads/NMSG-Poster_09.26.25.pdf)

<a id="topic-3.1.2.5-2"></a>

#### Protocol dose and comparison with background immunosuppression

> “The dose of Descartes-08 will be 52.5x10⁶ cells/kg, as determined in Part 1 and used in Part 2.”
> “Primary efficacy analysis will compare six once-weekly intravenous infusions of Descartes-08 plus background stable immunosuppression (up to 40 mg daily prednisone, azathioprine, methotrexate or mycophenolate mofetil) to six once-weekly intravenous infusions of placebo plus background stable immunosuppression.”

Source: [Cartesian Therapeutics MG-001 clinical study protocol, version 4.2 (2024)](https://pmc.ncbi.nlm.nih.gov/articles/instance/13004676/bin/41591_2025_4171_MOESM1_ESM.pdf)

<a id="topic-3.1.2.5-3"></a>

#### Additional antiemetic premedication

> “For participants reporting headaches and nausea in all or most of the six infusions, additional premedication with ondansetron was warranted.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using MGC Response as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint: 5-point or greater MGC decrease at month 3

> “The primary endpoint was the proportion of participants who demonstrated a ≥5-point decrease in the MGC score at month 3 compared to baseline.”
> “The MGC scale is a ten-item, 60-point weighted instrument composed of both patient-reported and provider-assessed items, which are themselves components of two other scales (MG-ADL and QMG).”
> “MGC was recommended by the 2000 MGFA Task Force for MG trials”
> “A 3-point change in the MGC score is considered clinically meaningful.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.6.1-2"></a>

##### Change of the primary outcome from MG-ADL to MGC, January 2024

> “On January 8, 2024, after the enrollment of 44 participants and before the unblinding of data and database lock, the steering committee of the trial, in consensus with the study monitoring committee, decided to implement a change in the primary outcome: from the MG-ADL score to the MGC score (previously a secondary outcome).”
> “The original primary outcome (MG-ADL score) was changed to a secondary outcome.”
> “This decision was made based on the recommendations of the 2000 MG Foundation of America (MGFA) Task Force”
> “with plans to use the MGC score as the primary outcome in a subsequent phase 3 trial.”
> “Consequently, the primary endpoint for this phase 2b study was a ≥5-point improvement in the MGC score at month 3.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.6.1-3"></a>

##### Rationale for the 5-point threshold: higher-than-expected baseline MGC scores

> “Notably, the 5-point improvement cutoff is higher than the 3-point decrease in the MGC score considered to be clinically meaningful.”
> “This threshold was chosen to account for the higher-than-expected baseline MGC score compared to the scores observed in the MGC validation set”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.6.1-4"></a>

##### Rationale for the 5-point threshold: company statement, July 2024

> “Whereas a reduction of three points or more is generally regarded as clinically meaningful, the more stringent endpoint of five points was selected based on clinical responses observed in an earlier study with Descartes-08 in MG.”

Source: [Cartesian Therapeutics phase 2b topline results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-topline-results-phase)

<a id="topic-3.1.2.6.1-5"></a>

##### Registered primary outcome measure

> “Proportion of patients with MG Composite improvement of ≥5 points.”

Source: [ClinicalTrials.gov NCT04146051](https://clinicaltrials.gov/study/NCT04146051)

<a id="topic-3.1.2.6.1-6"></a>

##### Secondary efficacy endpoints

> “Secondary efficacy endpoints were the mean change from baseline in MGC, MG-ADL, QMG and MG-QoL-15r scores at each postinfusion visit (months 2, 3, 4, 6, 9 and 12), as well as the proportion of participants with ≥2–8-point improvements in MG-ADL, QMG and MGC scores at each postinfusion visit.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.6.1-7"></a>

##### Registered secondary outcomes: 6-point responses and crossover participants

> “The proportion of patients achieving a ≥6-point change from Baseline at each posttreatment follow-up in the MG ADL score and QMG score (all parts), and the difference between this proportion in the treatment arm compared to placebo at Day 85.”
> “The proportion of patients initially randomized to placebo who then cross over to Descartes-08 and achieve a ≥5-point reduction in MGC score from Crossover Day 1 to Crossover Day 85.”

Source: [ClinicalTrials.gov NCT04146051](https://clinicaltrials.gov/study/NCT04146051)

<a id="topic-3.1.2.6.1-8"></a>

##### MG-ADL: instrument and clinically meaningful change

> “The MG-ADL scale is an eight-item, 24-point, patient-reported instrument that assesses the effects of gMG on daily functioning”
> “A 2-point change is considered clinically meaningful.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.6.1-9"></a>

##### QMG: instrument and clinically meaningful change

> “The QMG scale is a standardized, 39-point scoring system consisting of 13 provider-assessed items, which include hand-grip strength and forced vital capacity”
> “A 3-point change is considered clinically meaningful.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.6.1-10"></a>

##### MG-QoL-15r: instrument

> “The MG-QoL-15r scale is a 15-item, 30-point quality-of-life, patient-reported instrument with no consensus on what constitutes a clinically meaningful change”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.6.1-11"></a>

##### Safety endpoints

> “Safety endpoints included the occurrence of AEs and SAEs from the time of apheresis through month 12, as well as laboratory values and vital signs.”
> “AEs were coded using CTCAE version 5.0.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned sample size and power calculation

> “We estimated that 15 participants per treatment group would provide 80% power to detect a difference of 47% in responders between Descartes-08 and placebo.”
> “Calculations assumed 87% responders in the Descartes-08 group and 40% responders in the placebo group, based on a two-sample proportion test for independent samples to detect a difference in proportions at the 0.05 (nondirectional) level of significance.”
> “To account for screen failures and missed randomization due to insufficient cells manufactured, we enrolled up to 50 participants.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.7.1-2"></a>

##### Planned enrollment in the protocol

> “Part 3 of the study will enroll up to 50 additional patients (AchR+ and seronegative) to obtain 30 completers who will be randomized 1:1 to receive Descartes-08 or placebo via 6 weekly intravenous infusions.”

Source: [Cartesian Therapeutics MG-001 clinical study protocol, version 4.2 (2024)](https://pmc.ncbi.nlm.nih.gov/articles/instance/13004676/bin/41591_2025_4171_MOESM1_ESM.pdf)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants analyzed: safety population (36) and primary efficacy population (26)

> “Thirty-six participants were deemed eligible and randomized to receive Descartes-08 (n = 20) or placebo (n = 16), comprising the safety population.”
> “Twenty-six participants were enrolled in an academic institution and had at least one postinfusion follow-up available, and they comprised the primary efficacy population.”
> “Patients (n = 26) were randomly allocated to receive once-weekly intravenous infusions of Descartes-08 (n = 15) or placebo (n = 11) over 6 weeks.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants analyzed: company topline counts, July 2024, superseded in January 2026

> “The pre-specified primary efficacy dataset (n=26) consisted of a modified intent-to-treat (mITT) population of all subjects enrolled at academic medical centers who received at least one dose of Descartes-08 (n=14) or placebo (n=12) and completed at least one post-baseline MGC score follow-up assessment.”
> “The safety dataset comprised all subjects who received at least one dose of Descartes-08 (n=19) or placebo (n=17).”

Source: [Cartesian Therapeutics phase 2b topline results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-topline-results-phase)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Primary efficacy (mITT) population restricted to academic-center participants

> “Primary efficacy analyses were performed on a modified intention-to-treat (mITT) population, comprising all participants enrolled at an academic medical center who had at least one postbaseline follow-up.”
> “Baseline demographics and safety endpoints (that is, type and frequency of AEs) were analyzed in all enrolled participants using descriptive statistics.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.7.2-2"></a>

##### Protocol definitions of the mITT, ITT, and per-protocol populations

> “For Part 3, efficacy analysis will be conducted separately on an Intent-to-Treat (ITT) basis and a Per-Protocol (PP) basis.”
> “The analysis will be performed on mITT population, comprising all subjects in the ITT population as defined in the SAP enrolled at an academic medical center who have at least one post-Baseline follow-up.”
> “Sensitivity analyses in the overall ITT and PP populations will be reported.”
> “The PP population is a subset of the ITT population in which: 1) all participants have received all six doses of Descartes- 08 or placebo and have completed the Day 85 assessment”

Source: [Cartesian Therapeutics MG-001 clinical study protocol, version 4.2 (2024)](https://pmc.ncbi.nlm.nih.gov/articles/instance/13004676/bin/41591_2025_4171_MOESM1_ESM.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Primary endpoint analysis and handling of rescue and missing data

> “The primary endpoint—the response status at month 3 (day 85), in which responders were defined as those who had a reduction of 5 points or more in their MGC total score compared to baseline—was analyzed using a two-independent-sample proportion test at a two-sided 5% significance level; a Wald chi-squared test was used to determine whether there was a significant association between the treatment group and the response status.”
> “Participants who required rescue medication before day 85 had their MGC scores set to missing; these were imputed using baseline observation carried forward, with the response status set to nonresponder.”
> “All other missing data were imputed using multiple imputation, assuming data were missing at random.”
> “This was not required for the participants in the mITT population, as the data were complete.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.7.2-4"></a>

##### Subgroup analyses

> “Subgroup analyses were carried out to determine whether there was a difference in the response between participants who were anti-AChR antibody-positive and those who were anti-AChR antibody-negative, between those with early- and late-onset disease, between those with and without prior exposure to complement and FcRn inhibitors, and between those who did and did not develop a fever.”
> “The difference in the proportion of responders was assessed, and the Wald chi-squared test for association between response status and subgroup was performed separately within each treatment group.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.7.2-5"></a>

##### Follow-up efficacy dataset after month 3, company definition

> “The primary efficacy dataset for the follow-up portion of the trial consisted of a modified intent-to-treat (mITT) population of all subjects enrolled at academic medical centers who received at least one dose of Descartes-08 and completed at least one post-Month 3 MG Activities of Daily Living (MG-ADL) score follow-up assessment.”

Source: [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)

<a id="topic-3.1.2.7.2-6"></a>

##### Overall poster population combining per-protocol and mITT participants

> “Analyses were performed on the overall patient population, which comprised per-protocol and modified intention-to-treat patients (those enrolled at academic centers with at least one follow-up).”

Source: [Vu et al. (2025)](https://www.cartesiantherapeutics.com/wp-content/uploads/NMSG-Poster_09.26.25.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Screening, leukapheresis, and manufacturing failures before randomization

> “Of those, 45 participants met the inclusion criteria and underwent a single leukapheresis with a median of six doses produced (range, four to six doses).”
> “In accordance with the protocol, 9 of the 45 participants (20.0%) were not randomized; they received Descartes-08 under an open-label protocol because they failed to meet the therapeutic dose requirements for treatment, as fewer than six doses were manufactured (results to be reported separately).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.1-2"></a>

##### Withdrawal after two infusions

> “One of the participants randomized to Descartes-08 withdrew from the study for reasons other than safety or efficacy after two infusions, and subsequent labs were not analyzed; therefore, 35 total randomized patients were analyzed in the correlative/mechanistic study.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-3.1.2.8.1-3"></a>

##### Placebo participants crossed over to Descartes-08 after month 3

> “All 11 participants in the placebo group received Descartes-08 under an open-label protocol after the primary endpoint assessment at month 3, and treatment outcomes will be reported separately.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.1-4"></a>

##### Month 12 follow-up completion and loss to follow-up, March 2025 data cutoff

> “As of a March 31, 2025 cutoff date, 12 out of 15 participants who received Descartes-08 in the primary efficacy dataset completed their Month 12 follow-up assessments.”
> “Three participants, two of whom were MG Composite (MGC) responders at Month 3, were lost to follow-up after their Month 3 assessments.”

Source: [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline demographics and disease characteristics, mITT population

| Characteristic | Descartes-08 (n = 15) | Placebo (n = 11) | Total (n = 26) |
| --- | --- | --- | --- |
| Mean age, years (s.d.) | “56.7 (16.39)” | “59.0 (13.96)” | “57.7 (15.16)” |
| Female, n (%) | “10 (66.7)” | “6 (54.5)” | “16 (61.5)” |
| Mean weight, kg (s.d.) | “93.83 (20.001)” | “105.37 (27.496)” | “98.71 (23.669)” |
| White, non-Hispanic, n (%) | “13 (86.7)” | “11 (100.0)” | “24 (92.3)” |
| MGFA class IIa at screening, n (%) | “0” | “2 (18.2)” | “2 (7.7)” |
| MGFA class IIb at screening, n (%) | “4 (26.7)” | “1 (9.1)” | “5 (19.2)” |
| MGFA class IIIa at screening, n (%) | “2 (13.3)” | “5 (45.5)” | “7 (26.9)” |
| MGFA class IIIb at screening, n (%) | “8 (53.3)” | “3 (27.3)” | “11 (42.3)” |
| MGFA class IVa at screening, n (%) | “1 (6.7)” | “0” | “1 (3.8)” |
| Median age at disease onset, years (range) | “55 (16–76)” | “51 (25–71)” | “53 (16–76)” |
| Median duration of disease, years (range) | “5.5 (2–23)” | “10 (4–26)” | “6 (2–26)” |
| Anti-AChR antibody, n (%) | “11 (73.3)” | “8 (72.7)” | “19 (73.1)” |
| Anti-LRP4 antibody, n (%) | “1 (6.7)” | “0” | “1 (3.8)” |
| Triple seronegative, n (%) | “3 (20.0)” | “3 (27.3)” | “6 (23.1)” |
| Mean QMG score (s.d.) | “17.3 (7.31)” | “14.7 (4.03)” | “16.2 (6.17)” |
| Mean MG-ADL score (s.d.) | “10.5 (3.20)” | “9.8 (2.79)” | “10.2 (3.00)” |
| Mean MGC score (s.d.) | “16.4 (6.39)” | “15.7 (3.95)” | “16.1 (5.41)” |
| Mean MG-QoL-15r score (s.d.) | “19.1 (7.62)” | “17.7 (4.73)” | “18.5 (6.48)” |
| Diagnosis of thymoma, n (%) | “1 (6.7)” | “4 (36.4)” | “5 (19.2)” |
| Previous thymectomy, n (%) | “4 (26.7)” | “6 (54.5)” | “10 (38.5)” |
| Previous MG crisis requiring intubation, n (%) | “2 (13.3)” | “0” | “2 (7.7)” |

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.2-2"></a>

##### Previous and ongoing MG therapies, mITT population

| Therapy | Descartes-08 (n = 15) | Placebo (n = 11) | Total (n = 26) |
| --- | --- | --- | --- |
| Previous pyridostigmine, n (%) | “9 (60.0)” | “9 (81.8)” | “18 (69.2)” |
| Previous prednisone, n (%) | “7 (46.7)” | “5 (45.5)” | “12 (46.2)” |
| Previous other immunosuppressants, n (%) | “7 (46.7)” | “9 (81.8)” | “16 (61.5)” |
| Previous complement inhibitor, n (%) | “3 (20.0)” | “5 (45.5)” | “8 (30.8)” |
| Previous FcRn inhibitor, n (%) | “5 (33.3)” | “4 (36.4)” | “9 (34.6)” |
| Previous intravenous immunoglobulin, n (%) | “11 (73.3)” | “9 (81.8)” | “20 (76.9)” |
| Previous plasma exchange, n (%) | “3 (20.0)” | “6 (54.5)” | “9 (34.6)” |
| Ongoing pyridostigmine, n (%) | “11 (73.3)” | “7 (63.6)” | “18 (69.2)” |
| Ongoing prednisone, n (%) | “9 (60.0)” | “4 (36.4)” | “13 (50.0)” |
| Ongoing azathioprine, n (%) | “3 (20.0)” | “2 (18.2)” | “5 (19.2)” |
| Ongoing mycophenolate mofetil, n (%) | “3 (20.0)” | “6 (54.5)” | “9 (34.6)” |
| Ongoing complement inhibitor, n (%) | “4 (26.7)” | “1 (9.1)” | “5 (19.2)” |
| Number of concomitant MG therapies, median (range) | “2 (1–4)” | “2 (1–5)” | “2 (1–5)” |

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.2-3"></a>

##### Disease severity and antibody status, mITT population

> “Overall, 11 (73.3%) participants in the Descartes-08 group and 8 (72.7%) participants in the placebo group had MGFA class III or IV MG.”
> “Notably, two participants with MGFA class IIa MG were enrolled in the placebo group, whereas no participants with MGFA class IIa MG were enrolled in the Descartes-08 group.”
> “Of these, 19 (73.1%) were AChR autoantibody-positive, 1 (3.8%) was LRP4 autoantibody-positive and 6 (23.1%) were triple seronegative.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.2-4"></a>

##### Differences in concomitant therapy and prior biologic exposure between groups, mITT population

> “The proportion of participants reporting concomitant use of nonsteroidal immunosuppressants was lower in the Descartes-08 group than in the placebo group (n = 6, 40.0% versus n = 8, 73.0%).”
> “The median daily dose of concomitant prednisone equivalent was 20 mg (range, 5–25 mg) in the Descartes-08 group and 10 mg (range, 6–20 mg) in the placebo group, with no changes in dosing allowed before month 6.”
> “Almost half of the participants in the Descartes-08 group (n = 7/15, 40.0%) and 6 of 11 (54.5%) participants in the placebo group received prior or ongoing complement inhibitors, and a third of participants in both groups received an FcRn inhibitor as prior treatment for their MG, indicating the refractory nature of the disease in a large proportion of study participants.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.2-5"></a>

##### Baseline characteristics of all randomized participants (safety population)

| Characteristic | Placebo (n=16) | Descartes-08 (n=20) |
| --- | --- | --- |
| Female, % (n) | “62.5 (10)” | “55.0 (11)” |
| Age, years, mean (SD) | “57.8 (14.4)” | “59.4 (14.7)” |
| Median duration of disease, years (range) | “5 (1–23)” | “6 (0–26)” |
| MGFA class III at screening, % (n) | “68.8 (11)” | “70.0 (14)” |
| AChR+, % (n) | “75.0 (12)” | “80.0 (16)” |
| Sero-negative, % (n) | “25.0 (4)” | “15.0 (3)” |
| Diagnosis of thymoma, % (n) | “31.3 (5)” | “10.0 (2)” |
| Previous thymectomy, % (n) | “50.0 (8)” | “30.0 (6)” |
| Previous FcRn antagonist, % (n) | “37.5 (6)” | “30.0 (6)” |
| Previous complement inhibitor, % (n) | “37.5 (6)” | “15.0 (3)” |

Source: [Vu et al. (2025)](https://www.cartesiantherapeutics.com/wp-content/uploads/NMSG-Poster_09.26.25.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary endpoint and month 3 score changes, mITT population (Descartes-08 n = 15; placebo n = 11)

| Outcome at month 3 | Descartes-08 (n = 15) | Placebo (n = 11) |
| --- | --- | --- |
| MGC score, baseline, mean (s.d.) | “16.4 (6.39)” | “15.7 (3.95)” |
| MGC score, month 3, mean (s.d.) | “11.4 (8.57)” | “13.5 (8.48)” |
| MGC change from baseline at month 3, mean (s.d.) | “−5.0 (6.67)” | “−2.3 (7.73)” |
| MGC responder (≥5-point reduction), n (%) | “10 (66.7)” | “3 (27.3)” |
| MG-ADL score, baseline, mean (s.d.) | “10.5 (3.20)” | “9.8 (2.79)” |
| MG-ADL score, month 3, mean (s.d.) | “6.4 (4.31)” | “8.2 (3.82)” |
| MG-ADL change from baseline at month 3, mean (s.d.) | “−4.1 (3.38)” | “−1.6 (4.06)” |
| QMG score, baseline, mean (s.d.) | “17.3 (7.3)” | “14.7 (4.03)” |
| QMG score, month 3, mean (s.d.) | “13.4 (7.53)” | “13.2 (5.12)” |
| QMG change from baseline at month 3, mean (s.d.) | “−3.9 (4.37)” | “−1.5 (4.27)” |

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

| MGC responder comparison at month 3 | Value |
| --- | --- |
| Difference in proportions (95% CI) | “0.39 (0.01–0.77)” |
| P value | “0.0472” |

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary endpoint met at month 3, mITT population

> “At month 3, the proportion of patients achieving a ≥5-point improvement in the MGC score was significantly higher for those treated with Descartes-08 compared to placebo in the overall population (66.7% (n = 10/15) versus 27.3% (n = 3/11), P = 0.0472) and in a subpopulation of those positive for autoantibodies to the acetylcholine receptor (63.6% (n = 7/11) versus 12.5% (n = 1/8), P = 0.0258).”
> “Statistical significance was determined using a two-sided two-independent-sample proportion test.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.3-3"></a>

##### Primary endpoint, mITT population: company topline, July 2024, superseded in January 2026

> “The trial achieved its primary endpoint with statistical significance in the pre-specified mITT efficacy population, with 71% (10/14) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MGC score at Month 3 compared to 25% (3/12) of patients treated with placebo (p=0.018).”

Source: [Cartesian Therapeutics phase 2b topline results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-topline-results-phase)

<a id="topic-3.1.2.8.3-4"></a>

##### Primary endpoint, per-protocol population: company topline, July 2024

> “In addition, the trial also achieved its primary endpoint with statistical significance in the per-protocol population, with 69% (11/16) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MGC score at Month 3 compared to 33% (5/15) of patients treated with placebo (p=0.048).”

Source: [Cartesian Therapeutics phase 2b topline results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-topline-results-phase)

<a id="topic-3.1.2.8.3-5"></a>

##### MGC response and MG-ADL change at month 3, poster overall population (31 participants) and AChR+ population (24 participants), September 2025

| Population | Descartes-08 responders | Placebo responders | P value |
| --- | --- | --- | --- |
| “A. Overall population (n=31)” | “(n=12/18)” “67%” | “(n=4/13)” “31%” | “p value: 0.048” |
| “B. AChR+ population (n=24)” | “(n=9/14)” “64%” | “(n=2/10)” “20%” | “p value: 0.031” |

Source: [Vu et al. (2025)](https://www.cartesiantherapeutics.com/wp-content/uploads/NMSG-Poster_09.26.25.pdf)

> “The mean reduction in MG-ADL score at Month 3 was higher for the Descartes-08 treatment cohort versus placebo for both the overall (–4.0 versus –1.7) and AChR+ (–3.4 versus –0.9) patient populations.”

Source: [Vu et al. (2025)](https://www.cartesiantherapeutics.com/wp-content/uploads/NMSG-Poster_09.26.25.pdf)

<a id="topic-3.1.2.8.3-6"></a>

##### MG-ADL and QMG changes through month 12, Descartes-08 group, mITT population (open-label follow-up)

> “Responses deepened further during the follow-up for those in the Descartes-08 group, with the mean (s.d.) MG-ADL score reduction reaching −5.5 (1.1) at month 4 (day 113), which was maintained at month 12 (mean (s.d.) score, −4.8 (1.4)).”
> “QMG score reductions also continued throughout the follow-up period in the Descartes-08 group, reaching maximum improvement at month 12 (mean (s.d.) score, −6.0 (2.1)).”
> “For patients treated with Descartes-08, the changes from baseline in mean MGC, MG-ADL and QMG scores at month 4 were −7.1, −5.5 and −4.8, respectively, with 83.0% of patients achieving a sustained and clinically meaningful response at month 12.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “Participants treated with Descartes-08 were observed to have deep responses following initial treatment and sustained symptom improvement, with an average MG-ADL reduction of 5.5 (±1.1) at Month 4 and 4.8 (±1.4) at Month 12.”
> “Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at Month 4, which deepened through Month 12 (6.0±2.1).”

Source: [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)

<a id="topic-3.1.2.8.3-7"></a>

##### Sustained clinically meaningful MG-ADL response at month 12, Descartes-08 group, mITT population

> “In this phase 2b trial, the initial response rate was lower, with 10 of 15 participants (66.7%) achieving at least a 5-point improvement in the MGC score; however, all responses were maintained through 12 months, and 80.0% of participants had at least a clinically meaningful response 1 year after treatment, highlighting the durability of the effect.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “83% (10/12) of evaluable participants maintained a clinically meaningful response through Month 12. Clinically meaningful response is defined as a reduction in MG-ADL score of at least 2 points.”

Source: [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)

<a id="topic-3.1.2.8.3-8"></a>

##### Sustained response at month 12: company update, December 2024, superseded in April 2025

> “Responses were observed to be durable through Month 12, with 80% (4/5) of evaluable participants from the primary efficacy dataset maintaining a clinically meaningful response, defined as a reduction in MG-ADL score of at least 2 points.”

Source: [Cartesian Therapeutics phase 2b updated results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-updated-results-phase)

<a id="topic-3.1.2.8.3-9"></a>

##### Minimum symptom expression by month 6 and through month 12, Descartes-08 group, mITT population

> “Minimum symptom expression (MSE), defined as an MG-ADL score of ≤1, was achieved by 33.3% (n = 4/12) of participants in the Descartes-08 group who reached month 6 of follow-up, and all individuals maintained this status through month 12.”
> “Of those achieving MSE, two participants were AChR autoantibody-positive and two were triple seronegative.”
> “One participant in the placebo group who was triple seronegative achieved MSE status.”
> “Notably, 33.0% of patients achieved minimum symptom expression (MSE) (MG-ADL score ≤1) by month 6, which was sustained through month 12.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.3-10"></a>

##### Corticosteroid dose reduction and absence of therapy escalation through month 12

> “Tapering of the prednisone dose was allowed at the investigators’ discretion after the month 6 visit.”
> “After a median follow-up of 12 months, the median daily dose of orally administered prednisone equivalent in the Descartes-08 group was 9 mg (range, 2.5–20 mg), compared to 20 mg (range, 5–25 mg) at baseline—a 55.0% decrease.”
> “As there was no tapering allowed before month 6, the median dose in the placebo group remained unchanged throughout the follow-up at 10 mg (range, 6–20 mg).”
> “None of the participants randomized to Descartes-08 required escalation in MG therapies for the duration of the study, including intravenous infusion of immunoglobulin or plasma exchange.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.3-11"></a>

##### Placebo responses and secondary endpoint significance

> “There were several notable placebo responses during the early follow-up in the overall cohort.”
> “Although these responses were waning by the primary endpoint assessment at month 3, they led to a lack of statistical significance in the study’s secondary outcomes of efficacy.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.3-12"></a>

##### Anti-AChR antibody levels at month 3

> “While there was no difference between the groups in AChR autoantibody levels at month 3, an exploratory assay of all autoreactive antibodies showed a significant difference in the change at month 3 between Descartes-08 and placebo”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.3-13"></a>

##### Anti-AChR antibody levels at month 3: company presentation, October 2024, superseded in January 2026

> “Patients treated with Descartes-08 were observed to have a reduction in anti-acetylcholine receptor (AChR) antibody titer levels at three months, which is in line with findings from the previously completed Phase 2a trial, compared to an increase observed in patients receiving placebo.”

Source: [Cartesian Therapeutics MGFA 2024 presentation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-presentation-results-phase-2b)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### MG-QoL-15r, MG-ADL, and QMG change from baseline at month 3

> “At month 3, the Descartes-08 group demonstrated substantially greater numerical and clinically meaningful reductions compared to the placebo group in the mean MG-ADL score (4.1 versus 1.6), QMG score (−3.9 versus −1.5) and MG-QoL-15r score (−5.7 versus −3.7) (Fig. 2).”
> “All clinical outcome measures showed greater improvement in the Descartes-08 group compared with the placebo group, including patient-reported outcomes as measured by the MG-ADL score, objective improvements in patient strength as measured by the QMG score and the combination of the two measured by the MGC score.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.4-2"></a>

##### MG-QoL-15r and other scales among Descartes-08 responders at month 3, July 2024

> “Consistent with previously reported results from the Phase 2a open-label portion of the trial, Descartes-08 responders experienced deep improvements across the MG severity scales at Month 3 (average MG-ADL = -5.6; MGC= -8.3; QMG = -5.0; QoL-15r = -7.9).”

Source: [Cartesian Therapeutics phase 2b topline results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-topline-results-phase)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Treatment-emergent adverse events, day 1 to month 3, safety population

> “Treatment-emergent AEs from day 1 to month 3 for Descartes-08 and placebo”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

| Event, n (%) | Descartes-08 (n = 20) | Placebo (n = 16) |
| --- | --- | --- |
| Any AE | “17 (85.0)” | “13 (81.3)” |
| SAE | “5 (25.0)” | “3 (18.8)” |
| Any AE leading to discontinuation of study drug | “1 (5.0)” | “1 (6.3)” |
| Any infection | “8 (40.0)” | “6 (37.5)” |
| Upper respiratory infection | “3 (15.0)” | “4 (25.0)” |
| HSV reactivation | “3 (15.0)” | “0” |
| COVID-19 infection | “1 (5.0)” | “1 (6.3)” |
| Catheter-related infection | “1 (5.0)” | “0” |
| Urinary tract infection | “0” | “1 (6.3)” |
| Any IRR | “16 (80.0)” | “9 (56.3)” |
| Headache | “10 (50.0)” | “7 (43.8)” |
| Nausea | “9 (45.0)” | “4 (25.0)” |
| Fever | “11 (55.0)” | “1 (6.3)” |
| Chills | “12 (60.0)” | “0” |
| Myalgia | “7 (35.0)” | “0” |
| Fatigue | “7 (35.0)” | “1 (6.3)” |
| Limb swelling | “2 (10.0)” | “2 (12.5)” |
| Diarrhea | “3 (15.0)” | “1 (6.3)” |

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.5-2"></a>

##### Overall adverse events and grade 3 events, safety population

> “Adverse event (AE) rates were similar between groups, with 17 of 20 (85.0%) participants in the Descartes-08 group and 13 of 16 (81.3%) participants in the placebo group reporting at least one AE during the study (Table 3).”
> “Most AEs were mild or moderate (Common Terminology Criteria for AEs (CTCAE) grades 1–2).”
> “Among 20 participants in the safety population randomized to Descartes-08 and 16 participants randomized to placebo, 5 (25.0%) and 2 (12.5%), respectively, experienced a grade 3 AE.”
> “In the Descartes-08 group, grade 3 AEs included a vasovagal reaction, a bacterial infection, fever, a herpes simplex virus (HSV) reactivation and a thromboembolic event (thrombosis of a central venous port placed several years before enrollment).”
> “Meanwhile, grade 3 AEs reported in the placebo group included disease exacerbation and urinary tract infection.”
> “Of these, only the case of fever was deemed possibly treatment-related.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.5-3"></a>

##### Serious adverse events and absence of grade 4 or 5 events, safety population

> “There were no grade 4 or 5 (death) events in either group for the duration of the study (Table 3).”
> “Five serious AEs (SAEs) occurred in the Descartes-08 group (25.0%), while three SAEs occurred in the placebo group (18.8%).”
> “Of these, three in the Descartes-08 group and one in the placebo group occurred after the first infusion: one each of an infusion-related reaction (IRR), syncope, HSV reactivation and hip fracture.”
> “Of the three SAEs occurring after the first infusion in the Descartes-08 group, one (HSV reactivation) took place in an academic medical center, while two were reported in a community clinic.”
> “The only SAE deemed to be related to treatment was a grade 3 IRR manifesting as a fever of 40 °C, which started within 12 h of the fifth infusion and resolved within 48 h without the administration of tocilizumab or steroids.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.5-4"></a>

##### Infusion-related reactions: onset, management, and timing

> “Generally, IRRs manifested as an acute onset of headache, nausea, fever, chills, arthralgia and myalgia within 8 h of infusion.”
> “In all but one case (the above-mentioned grade 3 IRR), IRRs were managed in an outpatient setting and resolved within 24 h without tocilizumab or steroid administration.”
> “Fevers, chills and myalgias typically occurred after doses two through five for participants who experienced these AEs, with four of six grade 2 fevers (39–40 °C) occurring after the second and third infusions.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.5-5"></a>

##### Postinfusion fever and cytokine release syndrome classification

> “Due to the rapid onset and resolution of the severe fever without intervention, and in the absence of a concomitant increase in inflammatory markers commonly associated with cytokine release syndrome (CRS), this event was deemed to be an acute IRR.”
> “In our study, most participants randomized to Descartes-08 developed postinfusion fevers for approximately half of the administered infusions, which could be interpreted as grade 1 CRS”
> “However, several properties of the observed fevers do not support this interpretation.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.5-6"></a>

##### Infections and herpes simplex reactivation, safety population

> “Infection rates were similar between the treatment groups, with more upper respiratory infections reported in the placebo group than in the Descartes-08 group (25.0% versus 15.0%), while more HSV reactivations were reported in the Descartes-08 group compared to the placebo group (15.0% versus 0%) (Table 3).”
> “Notably, all HSV reactivations occurred in patients with a prior history of labial herpes who were on concomitant azathioprine.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.5-7"></a>

##### B cells, immunoglobulins, and vaccine titers

> “There was no difference in total circulating B cell levels between the Descartes-08 and placebo groups, and there were no cases of hypogammaglobulinemia.”
> “Serum levels of vaccine titers were similar between the two groups at month 3 and were maintained through month 12 in the Descartes-08 group.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.8.5-8"></a>

##### Adverse events after month 3 through month 12

> “There were no Descartes-08-related adverse events reported in Month 4 through Month 12 follow-up.”
> “Notably, there were no cases of cytokine release syndrome (CRS), and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS).”

Source: [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)

> “Of note, there was a Grade 2 upper respiratory infection reported in both the Descartes-08 and placebo groups.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-3.1.2.8.5-9"></a>

##### Treatment-emergent adverse events, AChR antibody-positive participants

| Event, n (%) | Descartes-08 (n=16) | Placebo (n=12) |
| --- | --- | --- |
| Any AE | “16 (100)” | “12 (100)” |
| Serious AE | “4 (25.0)” | “2 (16.7)” |
| Any AE leading to discontinuation of study drug | “1 (6.3)” | “1 (8.3)” |
| Any infusion-related reaction | “13 (81.3)” | “7 (58.3)” |
| Fever | “8 (50.0)” | “1 (8.3)” |
| Chills | “10 (62.5)” | “0” |
| Any infection | “6 (37.5)” | “5 (41.7)” |
| Herpes simplex reactivation | “2 (12.5)” | “0” |

Source: [Vu et al. (2026b)](https://www.cartesiantherapeutics.com/wp-content/uploads/260303_AChRP2B_Cartesian_MDA_oral-presentation_v4.0-Final.pdf)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- Sample size and power: the authors describe a phase 2 study with a limited sample size and 80% power to detect differences in the primary outcome, which makes comparisons of secondary outcomes descriptive. The power calculation assumed 15 participants per group, 87% responders with Descartes-08, and 40% with placebo. Numerical differences in secondary scores did not meet the hierarchical threshold for formal testing, and placebo responses during early follow-up led to a lack of statistical significance in the secondary efficacy outcomes.
- Analysis sets: of 45 participants who underwent leukapheresis, 9 (20.0%) were not randomized because fewer than six doses were manufactured. Of 36 randomized participants (safety population), the primary efficacy analysis included the 26 enrolled at an academic medical center with at least one postinfusion follow-up. The protocol specified sensitivity analyses in the overall ITT and per-protocol populations. The company's 2024 topline release reported the mITT population as 14 Descartes-08 and 12 placebo participants and the safety population as 19 and 17, where the published report gives 15 and 11, and 20 and 16.
- Change of primary endpoint: on January 8, 2024, after 44 participants had enrolled and before unblinding and database lock, the primary outcome was changed from the MG-ADL score to the MGC score, and the 5-point MGC threshold, chosen to account for higher-than-expected baseline MGC scores, exceeds the 3-point change considered clinically meaningful. The primary efficacy population was defined in protocol amendment v4.2 (June 19, 2024).
- Allocation and baseline imbalance: randomization had no stratification by site, and the authors state that this, the small sample, and the rate of participants not randomized likely led to unequal allocation. Disease duration and the rate of thymoma were higher in the placebo group, and triple seronegative participants (23.1%) were overrepresented compared with the general population, which the authors state affected the magnitude of the early placebo response. A transient effect of leukapheresis cannot be excluded.
- Subgroups: subgroup analyses compared participants by AChR antibody status, early- or late-onset disease (a prespecified analysis), prior exposure to complement and FcRn inhibitors, and development of fever, and an analysis of cell dose and MGC response was post hoc. The authors state that the small sample and heterogeneous population severely limit inferences about subgroups, and that the difference between biologic-naive and biologic-exposed participants may represent a true difference in biology, an artifact of a small sample size, or more treatment-refractory disease.
- Follow-up beyond month 3: all 11 placebo participants received open-label Descartes-08 after month 3, and month 4 to month 12 results are reported for the Descartes-08 group. As of a March 31, 2025 cutoff, the company reported that 12 of 15 Descartes-08 participants in the primary efficacy dataset completed month 12 and that 3 were lost to follow-up after month 3, 2 of whom were MGC responders at month 3.
- Other author-stated limitations: radioimmunoassay antibody testing may be insufficiently sensitive to changes in antibody subtype, mode of activity, and epitope; the protocol held prednisone stable until month 6 and allowed no change in nonsteroidal immunosuppressants; and fevers, chills, and myalgias were more common with Descartes-08 and may have affected the assessment of severity scales.
- Figures that differ between sources or within the report: sustained clinically meaningful response at month 12 is 83.0% in the abstract and 80.0% in the Discussion; minimum symptom expression is 33.0% in the abstract and 33.3% (4/12) in the Results; minimum symptom expression among biologic-naive participants is 55.60% in the abstract and 55.6% (5/9) in the Results, and the company's April 2025 release gives 57% (4/7) for biologic-naive participants with follow-up beyond month 3. The value −4.8 is reported both for the month-12 MG-ADL change and for the month-4 QMG change. The placebo MG-ADL change at month 3 in the AChR antibody-positive subgroup is 0.6 in the paper and −0.6 in a 2026 company slide presentation. The text reports prior or ongoing complement inhibitor use in the Descartes-08 group as “n = 7/15, 40.0%”.

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/); [Cartesian Therapeutics MG-001 clinical study protocol, version 4.2 (2024)](https://pmc.ncbi.nlm.nih.gov/articles/instance/13004676/bin/41591_2025_4171_MOESM1_ESM.pdf); [Cartesian Therapeutics phase 2b topline results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-topline-results-phase); [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and); [Vu et al. (2026b)](https://www.cartesiantherapeutics.com/wp-content/uploads/260303_AChRP2B_Cartesian_MDA_oral-presentation_v4.0-Final.pdf)

<a id="topic-3.1.2.9-2"></a>

#### Sample size, power, and descriptive secondary comparisons

> “First, although randomized and placebo-controlled, this was a phase 2 study with a limited sample size and modest power (80%) to detect differences in the primary outcome, making any comparisons in secondary outcomes purely descriptive.”
> “Numerical differences between treatment group scores did not meet the hierarchical threshold for formal testing and were, therefore, not analyzed for statistical significance.”
> “In combination with the heterogeneous population enrolled, in terms of both gMG antibody type and prior treatment history, the small sample size also severely limits any inferences that can be made about the subgroups.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.9-3"></a>

#### Allocation and baseline imbalance

> “The lack of stratification by site, combined with the small sample size and a higher-than-anticipated rate of enrolled participants not being randomized, likely led to unequal allocation between the active group and the placebo group.”
> “Second, due to the small sample size, there was an imbalance in several disease characteristics, such as disease duration and the rate of thymoma, both of which were higher in the placebo group.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.9-4"></a>

#### Overrepresentation of triple seronegative participants and possible leukapheresis effect

> “Third, although a minority of participants (23.1%) were triple seronegative, this was still an overrepresentation compared to the general population, significantly affecting the magnitude of the early response observed in the placebo group.”
> “Moreover, a transient effect of leukapheresis cannot be excluded, particularly as therapeutic plasma exchange is a common treatment option for refractory MG”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.9-5"></a>

#### Antibody assay sensitivity

> “Fourth, disease-specific antibodies were surveyed using radioimmunoassay in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, which, although in line with standard clinical practice, may be insufficiently sensitive to the changes in antibody subtype, mode of activity and epitope being targeted”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.9-6"></a>

#### Fixed background immunosuppression

> “Fifth, the protocol mandated keeping the dose of prednisone stable until the month 6 visit (limiting the time available for dose de-escalation to 6 months) and did not allow any changes in the dose of nonsteroidal immunosuppressants.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-3.1.2.9-7"></a>

#### Possible unblinding through infusion-related reactions

> “Finally, although the study team was blinded, the IRRs—specifically fevers, chills and myalgias—were more common in the Descartes-08 group and may have affected the assessment of gMG severity scales.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
